Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea
Globe Newswire•22/10/2026•08:30 ET
0
Key Highlights
- ➤Alpha Tau and Samsung Medical Center signed an MOU exploring a Korean pancreatic cancer trial
- ➤Potential trial would be Alpha DaRT’s first in South Korea, pending regulatory and ethics approvals
- ➤Alpha DaRT pancreatic cancer program could span six countries across North America, Europe, Middle East and Asia
- ➤Korean pancreatic cancer deaths rose over 6% in 2025, the steepest increase among major cancers
- ➤Samsung Medical Center performed more than 4,000 pancreatic cancer pancreatectomies between 2008 and 2025
Expert Statements
Uzi Sofer, CEO of Alpha Tau
“Signing this MOU with Samsung Medical Center, one of the world’s leading medical centers, is an important step forward in our goal to bring Alpha DaRT to cancer patients wherever they are. With Korea, our pancreatic cancer program could potentially span six countries across North America, Europe, the Middle East and Asia. I am grateful for SMC’s confidence in Alpha Tau and for the opportunity to explore the potential of Alpha DaRT to benefit its patients.”
Hee-Chul Kim, EVP of Samsung Medical Center and General Director of Samsung Comprehensive Cancer Center
“Pancreatic cancer remains one of the most challenging cancers to treat, and treatment options are limited for many patients. We hope this MOU will help us explore new possibilities for these patients. We will carefully review the clinical application of Alpha DaRT and do our best to strengthen our own research capabilities.”
- MOU relates to a potential clinical trial in South Korea, Alpha DaRT’s first, at Samsung Medical Center (SMC) in Seoul, ranked fifth in the world and number one in Korea in oncology -
- In Korea, only about one in five pancreatic cancer patients undergo surgery, and the disease’s death rate rose over 6% in 2025, the steepest increase among major cancers -
Get started
Create a free account to read the full story.